Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies
Abstract Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-19780-7 |
| _version_ | 1828238283163828224 |
|---|---|
| author | Xia Cao Junki Maruyama Heyue Zhou Yanwen Fu Lisa Kerwin Colin Powers Rachel A. Sattler John T. Manning Alok Singh Reyna Lim Laura D. Healy Sachi Johnson Elizabeth Paz Cabral Donghui Li Lucy Lu Arthur Ledesma Daniel Lee Susan Richards Laura Rivero-Nava Yan Li Weiqun Shen Karen Stegman Benjamin Blair Shinji Urata Magumi Kishimoto-Urata Jamie Ko Na Du Kyndal Morais Kate Lawrence Ianne Rivera Chin-I. Pai Damien Bresson Mark Brunswick Yanliang Zhang Henry Ji Slobodan Paessler Robert D. Allen |
| author_facet | Xia Cao Junki Maruyama Heyue Zhou Yanwen Fu Lisa Kerwin Colin Powers Rachel A. Sattler John T. Manning Alok Singh Reyna Lim Laura D. Healy Sachi Johnson Elizabeth Paz Cabral Donghui Li Lucy Lu Arthur Ledesma Daniel Lee Susan Richards Laura Rivero-Nava Yan Li Weiqun Shen Karen Stegman Benjamin Blair Shinji Urata Magumi Kishimoto-Urata Jamie Ko Na Du Kyndal Morais Kate Lawrence Ianne Rivera Chin-I. Pai Damien Bresson Mark Brunswick Yanliang Zhang Henry Ji Slobodan Paessler Robert D. Allen |
| author_sort | Xia Cao |
| collection | DOAJ |
| description | Abstract Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing. |
| first_indexed | 2024-04-12T21:01:08Z |
| format | Article |
| id | doaj.art-37fca7f29c8b45c4a5a9a070e9d4f804 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-12T21:01:08Z |
| publishDate | 2022-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-37fca7f29c8b45c4a5a9a070e9d4f8042022-12-22T03:16:50ZengNature PortfolioScientific Reports2045-23222022-09-0112111210.1038/s41598-022-19780-7Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodiesXia Cao0Junki Maruyama1Heyue Zhou2Yanwen Fu3Lisa Kerwin4Colin Powers5Rachel A. Sattler6John T. Manning7Alok Singh8Reyna Lim9Laura D. Healy10Sachi Johnson11Elizabeth Paz Cabral12Donghui Li13Lucy Lu14Arthur Ledesma15Daniel Lee16Susan Richards17Laura Rivero-Nava18Yan Li19Weiqun Shen20Karen Stegman21Benjamin Blair22Shinji Urata23Magumi Kishimoto-Urata24Jamie Ko25Na Du26Kyndal Morais27Kate Lawrence28Ianne Rivera29Chin-I. Pai30Damien Bresson31Mark Brunswick32Yanliang Zhang33Henry Ji34Slobodan Paessler35Robert D. Allen36Sorrento Therapeutics, Inc.Galveston National Laboratory, Department of Pathology, University of Texas Medical BranchSorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Galveston National Laboratory, Department of Pathology, University of Texas Medical BranchGalveston National Laboratory, Department of Pathology, University of Texas Medical BranchSorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Galveston National Laboratory, Department of Pathology, University of Texas Medical BranchGalveston National Laboratory, Department of Pathology, University of Texas Medical BranchSorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Sorrento Therapeutics, Inc.Galveston National Laboratory, Department of Pathology, University of Texas Medical BranchSorrento Therapeutics, Inc.Abstract Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.https://doi.org/10.1038/s41598-022-19780-7 |
| spellingShingle | Xia Cao Junki Maruyama Heyue Zhou Yanwen Fu Lisa Kerwin Colin Powers Rachel A. Sattler John T. Manning Alok Singh Reyna Lim Laura D. Healy Sachi Johnson Elizabeth Paz Cabral Donghui Li Lucy Lu Arthur Ledesma Daniel Lee Susan Richards Laura Rivero-Nava Yan Li Weiqun Shen Karen Stegman Benjamin Blair Shinji Urata Magumi Kishimoto-Urata Jamie Ko Na Du Kyndal Morais Kate Lawrence Ianne Rivera Chin-I. Pai Damien Bresson Mark Brunswick Yanliang Zhang Henry Ji Slobodan Paessler Robert D. Allen Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies Scientific Reports |
| title | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_full | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_fullStr | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_full_unstemmed | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_short | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies |
| title_sort | unbiased approach to identify and assess efficacy of human sars cov 2 neutralizing antibodies |
| url | https://doi.org/10.1038/s41598-022-19780-7 |
| work_keys_str_mv | AT xiacao unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT junkimaruyama unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT heyuezhou unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT yanwenfu unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT lisakerwin unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT colinpowers unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT rachelasattler unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT johntmanning unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT aloksingh unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT reynalim unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT lauradhealy unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT sachijohnson unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT elizabethpazcabral unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT donghuili unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT lucylu unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT arthurledesma unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT daniellee unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT susanrichards unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT laurariveronava unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT yanli unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT weiqunshen unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT karenstegman unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT benjaminblair unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT shinjiurata unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT magumikishimotourata unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT jamieko unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT nadu unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT kyndalmorais unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT katelawrence unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT iannerivera unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT chinipai unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT damienbresson unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT markbrunswick unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT yanliangzhang unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT henryji unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT slobodanpaessler unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies AT robertdallen unbiasedapproachtoidentifyandassessefficacyofhumansarscov2neutralizingantibodies |